决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:GD2-CAR CAR T cells in patients with osteosarcoma and neuroblastoma-it's not only the T cells that matter.
GD2-CAR T 细胞是安全的,但抗肿瘤反应有限。
GD2-CAR T细胞安全性良好,但抗肿瘤应答有限。本期《Cancer Cell》中,Kaczanowska等人发现,在CAR-T扩增良好者中,单采产品和基线外周血均含有显著更高比例的CXCR3+单核细胞。CXCR3+单核细胞可能影响CAR-T细胞功能。
GD2-CAR T cells were safe and anti-tumor responses were limited. In this issue of Cancer Cell, Kaczanowska et al. find that apheresis products and peripheral blood at baseline contained significantly higher proportions of CXCR3+ monocytes in good expanders. CXCR3+ monocytes may influence CAR T cell function.
MEMBER ACCOUNT
登录成功会直接打开下一页。